Piperacillin-Tazobactam

C. diff Risk

Medium

Oral Bioavailability

NA

Approximate Cost

Dosing

Adult

Usual dosage range: 4.5 g IV q8h

For coverage of *Pseudomonas aeruginosa:* 4.5 g q6h
(HAP or VAP dosing)

General Information

Common Usage

Broad spectrum agent with anti-pseudomonal activity.

Used for severe infections including:

  •  Pneumonia

  •  Intra-abdominal/hepatobiliary

  •  UTI

  •  Polymicrobial skin and soft tissue infection

  •  Febrile neutropenia

Adverse Effects

  • Allergy/rash (immediate or delayed)

  • Cytopenias- esp. thrombocytopenia

  • Eosinophilia

  • Interstitial nephritis

  • Abnormal liver enzymes

Major Interactions

Avoid use with intravesicular BCG, Typhoid vaccine and Cholera Vaccine due to decreased effect
Increased levels of:
- methotrexate
- vancomycin
- Vecuronium
- Warfarin/Vitamin K antagonists
Decreased levels of:
- aminoglycosides
- mycophenolate
May result in false positive Coomb's test.
Tetracyclines may decrease levels of Piperacillin-Tazobactam

Pharmacology

Antimicrobial class: Ureidopenicillin with a beta-lactamase inhibitor

Pregnancy category: B

Average serum half life: 1 hour

Biliary penetration: Therapeutic

CSF penetration: Poor overall CSF penetration.
Moderate CNS penetration with inflamed meninges, may not be effective for P. aeruginosa

Lung penetration: Therapeutic

Urine penetration: Therapeutic